POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.43 CHF | -13.53% |
|
-43.74% | -6.22% |
| 03-12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| 03-12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
| Sales 2024 * | 345M 371M 336M 29.63B | Sales 2025 * | 407M 438M 396M 34.89B | Capitalization | 1B 1.08B 973M 85.8B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -12.91M -11.68M -1.03B | Net income 2025 * | 14M 15.07M 13.63M 1.2B | EV / Sales 2024 * | 3.17 x |
| Net Debt 2024 * | 93.91M 101M 91.42M 8.06B | Net Debt 2025 * | 132M 142M 128M 11.3B | EV / Sales 2025 * | 2.78 x |
| P/E ratio 2024 * |
-118
x | P/E ratio 2025 * |
64.7
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.15% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | -13.53% | ||
| 1 week | -43.74% | ||
| Current month | -45.78% | ||
| 1 month | -41.84% | ||
| 3 months | +8.02% | ||
| 6 months | -19.14% | ||
| Current year | -6.22% |
1 week
16.43
30.85
1 month
16.4330.85
Current year
14.1930.90
1 year
14.1930.90
3 years
14.19145.02
5 years
14.19145.02
10 years
14.19145.02
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 11/04/23 | |
| Chief Tech/Sci/R&D Officer | 52 | 31/12/11 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 30/11/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 31/12/20 | |
Peter Wilden
CHM | Chairman | 67 | 31/03/21 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 31/12/05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 29.65 | -2.36% | 1,554 |
| 02/05/24 | 30.37 | +0.22% | 1,114 |
| 30/04/24 | 30.3 | -0.49% | 760 |
| 29/04/24 | 30.45 | +4.26% | 1,584 |
| 26/04/24 | 29.21 | -0.32% | 3,455 |
Delayed Quote London S.E., February 21, 2024 at 04:54 pm
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
12/08/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.32
EUR
Average target price
22.24
EUR
Spread / Average Target
-26.67%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- PPGN Stock
- 0AAJ Stock
